Information concerning the number of prostate specific antigen (PSA) tests that take place in the national health service each year and the cost of individual PSA tests are not held centrally. However, we understand the average price is in the region of £35. The commissioning and pricing of PSA tests is a local matter. Expenditure data relating to the treatment of patients suffering from prostate cancer is not available in the format requested. Programme budgeting data collected from primary care trusts (PCTs) can provide estimated aggregate PCT expenditure on urological cancers, which includes prostate cancer. In the following table, NHS England has provided data for NHS spend on urological cancers in 2011-12, the latest financial year for which this data is available. It is important to note that it is not always possible for commissioners to break down their expenditure to a specific programme category, therefore not all expenditure relating to the identification and treatment of cancers and tumours will be included within this estimate. Areas of expenditure that are difficult to estimate include general practitioner costs, diagnostic imaging and community care costs. Not all expenditure on radiotherapy, chemotherapy or high cost drugs will be included within the estimate of urological cancers, and will be included instead within the “Cancers and Tumours (Other)” category. EstimatedNHS expenditure on cancer and tumours in2011-12 £million Allcancers andtumours 5,501 Urologicalcancers 354 Cancersand tumours(Other) 2,998